This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

DARA BioSciences Names Timothy Heady, Former CEO Of UnitedHealthcare Pharmacy, To Its Board

DARA BioSciences, Inc. ( NASDAQ: DARA), a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care products, announced today the appointment of Timothy J. Heady to the DARA board of directors. The appointment is the second new board member DARA has announced over the past two months and brings the total number of directors to six.

Mr. Heady retired in 2011 as CEO of UnitedHealthcare Pharmacy, a unit of UnitedHealthcare (NYSE: UNH) representing more than $11 Billion in annual prescription drug spending. In that role, he was responsible for all aspects of the business, including pharmaceutical rebate contracting, retail pharmacy network development, customer and member services, operations, and financial performance. UnitedHealthcare Pharmacy provides pharmacy benefits and management for employers, both commercial and government, representing more than 14 million individuals. Prior to joining UnitedHealthcare in 2001, Mr. Heady was a senior executive with Searle/Pharmacia where he managed the Customer Operations unit, including national customer sales and marketing. Mr. Heady served on the board of directors for the Center for Diagnostic Imaging, Inc., a privately held radiology business based in Minnesota. He has also served on the board for Age Wave Impact, Inc., a full-service marketing company focused on baby boomers. Mr. Heady earned a Bachelors of Science degree in management from Purdue University, an MBA from Northwestern University's Kellogg School of Management, and he is a Certified Public Accountant.

Commenting on the announcement, Dr. David J. Drutz, DARA’s chief executive officer, stated, "Tim is another significant addition to the DARA board. His experience in pharmacy and specialty drug management, pharmacy benefits design, and with third-party payers will be of primary relevance to DARA as we continue to grow our oncology-focused specialty pharmaceutical business."

Dr. Drutz continued, "Tim Heady's appointment as well as the recent addition of Stephen Jaeger to the DARA board reflects the ongoing evolution of both the company and its board of directors.” On August 20, 2012, DARA filed an 8K with the SEC announcing the resignation of two board members. “With these new appointments, we continue to strengthen the company’s foundation. Each of these individuals brings a wealth of operational experience and a deep understanding of public companies in the biopharmaceutical, pharmacy benefit, medical and financial areas. They will be of great value as DARA moves forward, including helping us evaluate new near-term product opportunities.”

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,096.90 -106.47 -0.58%
S&P 500 2,098.53 -9.25 -0.44%
NASDAQ 4,967.1410 -12.76 -0.26%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs